[go: up one dir, main page]

PE20160041A1 - FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA - Google Patents

FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA

Info

Publication number
PE20160041A1
PE20160041A1 PE2015002176A PE2015002176A PE20160041A1 PE 20160041 A1 PE20160041 A1 PE 20160041A1 PE 2015002176 A PE2015002176 A PE 2015002176A PE 2015002176 A PE2015002176 A PE 2015002176A PE 20160041 A1 PE20160041 A1 PE 20160041A1
Authority
PE
Peru
Prior art keywords
triazol
pyridin
ethyl
methyl
methods
Prior art date
Application number
PE2015002176A
Other languages
English (en)
Inventor
Anil Menon
Darshan K Parikh
Dora Visky
Matthew Michael Kreilein
Nathan Boersen
Thomas Lee
Ying Li
Jean Xu
Xiaozhang Liang
William Wei-Hwa Leong
Benjamin Cohen
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of PE20160041A1 publication Critical patent/PE20160041A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a formulaciones, formas solidas y metodos de obtencion de 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il) piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona o un tautomero del mismo como 1-etil-7-(2-metil-6-(4H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona o 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-5-yl)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1 H)-ona, util en el tratamiento de cancer, enfermedades inflamatorias cronica, diabetes y apoplejia
PE2015002176A 2013-04-17 2014-04-16 FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA PE20160041A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361813064P 2013-04-17 2013-04-17
US201361911201P 2013-12-03 2013-12-03

Publications (1)

Publication Number Publication Date
PE20160041A1 true PE20160041A1 (es) 2016-01-28

Family

ID=50792565

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002176A PE20160041A1 (es) 2013-04-17 2014-04-16 FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA

Country Status (24)

Country Link
US (3) US9359364B2 (es)
EP (2) EP2986609B1 (es)
JP (2) JP2016516815A (es)
KR (2) KR20160004273A (es)
CN (2) CN105324381A (es)
AU (1) AU2014254050B2 (es)
BR (1) BR112015026300A2 (es)
CA (1) CA2909629C (es)
CL (1) CL2015003068A1 (es)
CR (1) CR20150577A (es)
EA (2) EA030726B1 (es)
ES (1) ES2744198T3 (es)
HK (1) HK1221951A1 (es)
IL (1) IL242102B (es)
MX (2) MX380236B (es)
NI (1) NI201500152A (es)
NZ (2) NZ730189A (es)
PE (1) PE20160041A1 (es)
PH (2) PH12015502394A1 (es)
SA (1) SA515370014B1 (es)
SG (1) SG11201508527VA (es)
TW (1) TW201527300A (es)
WO (1) WO2014172423A1 (es)
ZA (1) ZA201507737B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
US9474757B2 (en) 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
MX377267B (es) 2013-04-17 2025-03-07 Signal Pharm Llc Tratamiento de cáncer con dihidropirazino-pirazinas.
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
PE20160041A1 (es) * 2013-04-17 2016-01-28 Signal Pharm Llc FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA
WO2014193912A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) * 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2018152095A1 (en) * 2017-02-14 2018-08-23 Celgene Corporation Treatment of cancer with smg1-inhibitors
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
CN118940156B (zh) * 2024-10-15 2024-12-13 贵州健易测科技有限公司 一种基于大数据分析的食品风味评定方法及系统

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US3567725A (en) 1968-11-20 1971-03-02 Merck & Co Inc Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
US4294837A (en) 1980-03-28 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
US4294836A (en) 1980-03-24 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
US4317909A (en) 1980-03-24 1982-03-02 Sterling Drug Inc. Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
US4309537A (en) 1980-03-28 1982-01-05 Sterling Drug Inc. Production of imidazo[4,5-b]pyridin-2-ones or thiones
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
JPS63275582A (ja) 1987-05-02 1988-11-14 Naade Kenkyusho:Kk ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法
DD262026A1 (de) 1987-07-10 1988-11-16 Akad Wissenschaften Ddr Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
US4963561A (en) 1990-02-28 1990-10-16 Sterling Drug Inc. Imidazopyridines, their preparation and use
TW274550B (es) 1992-09-26 1996-04-21 Hoechst Ag
DE19601627A1 (de) 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
US6031105A (en) 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
NZ503432A (en) 1997-09-26 2002-11-26 Zentaris Gmbh Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
AU750564B2 (en) 1997-11-27 2002-07-25 Chugai Seiyaku Kabushiki Kaisha Examination method, examination reagent and remedy for diseases caused by variation in LKB1 gene
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
JP2003146987A (ja) 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
EP1186232A4 (en) 1999-05-31 2004-11-10 Chugai Pharmaceutical Co Ltd 'KNOCKOUT' ANIMALS LACKING THE LKB1 GENE
JP3814125B2 (ja) 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
JP2002100363A (ja) 2000-09-25 2002-04-05 Mitsubishi Chemicals Corp リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
JP2002167387A (ja) 2000-11-29 2002-06-11 Dainippon Pharmaceut Co Ltd ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体
EP1347982B1 (en) 2000-12-12 2005-11-16 Neurogen Corporation Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
PL369740A1 (en) 2001-09-04 2005-05-02 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
WO2003032989A1 (en) 2001-10-18 2003-04-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
MY156407A (en) 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
WO2004042002A2 (en) 2002-08-05 2004-05-21 University Of Massachusetts Compounds for modulating rna interference
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
ATE527250T1 (de) 2002-11-21 2011-10-15 Novartis Ag 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
PT1599478E (pt) 2003-02-26 2007-05-31 Boehringer Ingelheim Pharma Di-hidropteridinonas, proceso para a sua preparação e a sua utilização como medicamento
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
PL1633766T3 (pl) 2003-05-30 2019-09-30 Gilead Pharmasset Llc Modyfikowane fluorowane analogi nukleozydów
JP4705912B2 (ja) 2003-06-26 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション ベンゾジアゼピンｃｇｒｐ受容体拮抗物質
JP2007530000A (ja) 2003-07-17 2007-11-01 ユニヴァーシティー オブ ダンディー Ｌｋｂ１／ｓｔｒａｄ７ｍ０２５複合体の使用方法
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
US20080194019A1 (en) 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
US20090186929A1 (en) * 2003-11-10 2009-07-23 U.S. Department Of Veterans Affairs Method and agent for inducing apoptosis/cell death in leukemia cells
WO2005120511A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006001266A1 (ja) 2004-06-23 2006-01-05 Banyu Pharmaceutical Co., Ltd. ２－アリールプリン誘導体の製造方法
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7608622B2 (en) 2004-09-24 2009-10-27 Janssen Pharmaceutica Nv Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
MX2007005159A (es) 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
AU2005316668B2 (en) 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2008531538A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用
CA2599320A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
MX2007012393A (es) 2005-04-05 2008-02-22 Pharmacopeia Inc Derivados de purina e imidazopiridina para la inmunosupresion.
AU2006302148B2 (en) 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
HRP20130902T1 (hr) 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
WO2007047754A2 (en) 2005-10-18 2007-04-26 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
HRP20110553T1 (hr) 2005-11-17 2011-09-30 Osi Pharmaceuticals FUZIONIRANI BICIKLIČKI INHIBITORI mTOR
AU2006318948B2 (en) 2005-11-22 2011-02-24 Kudos Pharmaceuticals Limited Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
GB0525083D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
KR20080083188A (ko) 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
CN101472930B (zh) 2006-04-26 2011-12-14 霍夫曼-拉罗奇有限公司 用作PI3K抑制剂的噻吩并[3,2-d]嘧啶的衍生物
WO2007129052A1 (en) 2006-05-03 2007-11-15 Astrazeneca Ab Pyrazole derivatives and their use as pi3k inhibitors
EP2016075A1 (en) 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
EP2995619B1 (en) 2006-08-02 2019-09-25 Cytokinetics, Inc. Certain chemical entities comprising imidazopyrimidines, compositions and methods
AU2007287430B2 (en) 2006-08-23 2011-07-21 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
CA2662677C (en) 2006-09-05 2016-05-31 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
US20100144738A1 (en) 2006-09-05 2010-06-10 William Bornmann Inhibitors of c-met and uses thereof
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032064A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
CN101563339A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 作为 p i 3 k和 m t o r抑制剂用于治疗增殖性疾病的 2 -苯并咪唑基 - 6 -吗啉代 - 4 - (氮杂环丁烷、吡咯烷、哌啶或氮杂)嘧啶衍生物
WO2008032077A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032027A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
EP2064203A1 (en) 2006-09-14 2009-06-03 AstraZeneca AB 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
EP2090577B1 (en) 2006-10-19 2017-04-05 Signal Pharmaceuticals, LLC Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
KR101451290B1 (ko) 2006-10-19 2014-10-15 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
JP5562033B2 (ja) 2006-11-20 2014-07-30 ノバルティス アーゲー ２−メチル−２−［４−（３−メチル−２−オキソ−８−キノリン−３−イル−２，３−ジヒドロ−イミダゾ［４，５−ｃ］キノリン−１−イル）−フェニル］−プロピオニトリルの塩および結晶形態
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US8263329B2 (en) * 2007-03-29 2012-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
US8138183B2 (en) 2007-07-09 2012-03-20 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
CA2692945A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Compounds - 945
AU2008273892A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
US8129371B2 (en) 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2009205501A1 (en) 2008-01-15 2009-07-23 Wyeth Llc 3H-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their syntheses
WO2009102986A1 (en) 2008-02-15 2009-08-20 Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox1 inhibitor
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
SI2477987T1 (en) 2009-09-14 2018-03-30 Gilead Sciences, Inc. MODULATORS TO TOLL OF LIKE RECEPTORS
AU2010313585B2 (en) * 2009-10-26 2015-11-26 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
US8445503B2 (en) 2009-12-23 2013-05-21 Elan Pharmaceuticals, Inc. Inhibitors of polo-like kinase
NZ601581A (en) 2010-02-03 2014-03-28 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
US20110318336A1 (en) 2010-03-29 2011-12-29 George Mason Intellectual Properties, Inc. Identification and Treatment of Aggressive Lung Cancer Tumors
US20120028972A1 (en) 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling
US20130158023A1 (en) 2011-08-03 2013-06-20 Signal Pharmaceuticals, Llc Identification of gene expression as a predictive biomarker for lkb1 status
ES2894958T3 (es) 2011-10-19 2022-02-16 Signal Pharm Llc Tratamiento del cáncer con inhibidores de la quinasa TOR
ES2694413T3 (es) 2011-12-02 2018-12-20 Signal Pharmaceuticals, Llc Composiciones farmacéuticas de 7-(6-(2-hidroxipropan-2-il)piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino [2,3-b]pirazin-2(1H)-ona, una forma sólida de la misma y métodos para su uso
JP6114317B2 (ja) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
SG11201405686PA (en) 2012-03-15 2014-10-30 Signal Pharm Llc Treatment of cancer with tor kinase inhibitors
WO2013138557A1 (en) 2012-03-15 2013-09-19 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
SG11201405724RA (en) 2012-03-15 2014-10-30 Signal Pharm Llc Treatment of cancer with tor kinase inhibitors
KR20190058673A (ko) 2012-03-15 2019-05-29 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
JP6389241B2 (ja) 2013-04-17 2018-09-12 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのＴＯＲキナーゼ阻害剤及びＩＭｉＤ化合物を含む組合せ療法
PE20160041A1 (es) * 2013-04-17 2016-01-28 Signal Pharm Llc FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
MX377267B (es) 2013-04-17 2025-03-07 Signal Pharm Llc Tratamiento de cáncer con dihidropirazino-pirazinas.
US9474757B2 (en) * 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP2986297A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Treatment of cancer with dihydropyrazino-pyrazines
NZ631082A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160868A1 (en) * 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160880A1 (en) * 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) * 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use

Also Published As

Publication number Publication date
MX393164B (es) 2025-03-21
SA515370014B1 (ar) 2018-06-27
JP2018150356A (ja) 2018-09-27
NZ730189A (en) 2018-09-28
KR20160004273A (ko) 2016-01-12
EA037683B1 (ru) 2021-04-29
EA201591989A1 (ru) 2016-04-29
CA2909629A1 (en) 2014-10-23
WO2014172423A1 (en) 2014-10-23
CR20150577A (es) 2016-03-30
AU2014254050B2 (en) 2018-10-04
PH12015502394A1 (en) 2016-02-22
EA201890933A2 (ru) 2018-09-28
IL242102B (en) 2020-01-30
ES2744198T3 (es) 2020-02-24
EP2986609A1 (en) 2016-02-24
EP2986609B1 (en) 2019-06-19
EA030726B1 (ru) 2018-09-28
SG11201508527VA (en) 2015-11-27
JP2016516815A (ja) 2016-06-09
TW201527300A (zh) 2015-07-16
US20160250210A1 (en) 2016-09-01
JP6517979B2 (ja) 2019-05-22
NZ629230A (en) 2017-05-26
US20140315908A1 (en) 2014-10-23
CL2015003068A1 (es) 2016-09-09
EP3549940A1 (en) 2019-10-09
US9827243B2 (en) 2017-11-28
ZA201507737B (en) 2017-05-31
HK1221951A1 (zh) 2017-06-16
PH12018501137B1 (en) 2022-01-07
BR112015026300A2 (pt) 2017-07-25
KR102459285B1 (ko) 2022-10-27
PH12018501137A1 (en) 2019-03-25
MX380236B (es) 2025-03-12
NI201500152A (es) 2015-11-30
CN111166751A (zh) 2020-05-19
AU2014254050A1 (en) 2015-11-12
US9359364B2 (en) 2016-06-07
CN105324381A (zh) 2016-02-10
MX2015014677A (es) 2016-02-19
US10052322B2 (en) 2018-08-21
EA201890933A3 (ru) 2019-02-28
KR20210090287A (ko) 2021-07-19
US20180042924A1 (en) 2018-02-15
CA2909629C (en) 2022-12-13

Similar Documents

Publication Publication Date Title
PE20160041A1 (es) FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA
ME03470B (me) 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo [1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za upotrebu u liječenju kancera
CL2013002063A1 (es) Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune.
IL256828B (en) 1-ethyl-7-(2-methyl-6-(4h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3b]pyrazin-2(1h)-one for treatment of cancer
CL2014002412A1 (es) Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
PH12015502780B1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
CL2014002557A1 (es) Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.
PH12017500163A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
IL241950B (en) Compound 1-ethyl-7-(2-methyl-6-(1h-4,2,1-triazol-3-yl)pyridin-3-yl)-4,3-dihydropyrazino[2,3-b]pyrazine- 2(1h)-ven for the treatment of glioblastoma multiforme
CL2014000641A1 (es) Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras.
MX2013011421A (es) Derivados de pirazolo-pirimidina.
HRP20182021T1 (hr) Derivati [1,2,4]triazolo[1,5-a]pirimidina kao inhibitori proteazoma protozoe za liječenje parazitskih bolesti poput lišmenijaze
EP3131553A4 (en) SOLID FORMS OF 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE
EP3131551A4 (en) SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
MX2015015880A (es) Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida del mismo y metodos de su uso.
CL2014001425A1 (es) Composicion farmaceutica de 7-(6-(2-hidroxipropan-2-il) piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona o forma solida del mismo y uso para tratar o prevenir enfermedades tales como cancer, diabetes, obesidad, entre otras.
TH1501006326A (th) สูตรผสมทางเภสัชกรรม, กระบวนการ, รูปแบบของแข็ง และวิธีของการใช้ที่เกี่ยวข้องกับ 1-เอธิล-7-(2-เมธิล-6-(1h-1,2,4-ไทรอะโซล-3-อิล) ไพริดิน-3-อิล)-3,4-ไดไฮโดรไพราซิโน[2,3-b]ไพราซิน-2(1h)-โอน
HK1236035A1 (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
HK1236034A1 (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MA40553A (fr) Dérivés de pyrimidine substitués par un hétérocyclyle éventuellement condensés utiles pour le traitement des maladies inflammatoires, métaboliques, oncologiques et auto-immunes

Legal Events

Date Code Title Description
FD Application declared void or lapsed